Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$42.57 USD

42.57
740,451

-0.06 (-0.14%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $42.57 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.

Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Record shipments for both clinical and research with strength in oncology testing, genetic disease testing, and population genomics drove Illumina (ILMN) Q4 revenues.

AMN Healthcare Services (AMN) Stock Moves -1.46%: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $103.75 in the latest trading session, marking a -1.46% move from the prior day.

AMN Healthcare Services (AMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

AMN Healthcare (AMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Here's Why You Should Retain Abbott (ABT) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.

STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.

Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Baxter's (BAX) strong product portfolio.

What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?

by Zacks Equity Research

Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.

AMN Healthcare (AMN) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength across its business segments.

CVS Health (CVS) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Strength in all three operating segments drove CVS Health's (CVS) revenues in the fourth quarter of 2021.

QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Increase in number of orders for Cologuard and new study findings supporting the Oncotype DX are likely to have contributed to Exact Sciences' (EXAS) Q4 performance.

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

AMN Healthcare (AMN) Moves to Strong Buy: Rationale Behind the Upgrade

by Zacks Equity Research

AMN Healthcare (AMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays

by Zacks Equity Research

IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

New Strong Buy Stocks for February 8th

by Zacks Equity Research

AMN, COP, RL, SM, and WHR have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2022.

Here's Why You Should Add Quidel (QDEL) Stock To Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.